Home/Pipeline/BI 1701963

BI 1701963

KRAS-mutant solid tumors

Phase 1Active

Key Facts

Indication
KRAS-mutant solid tumors
Phase
Phase 1
Status
Active
Company

About Boehringer Ingelheim

Boehringer Ingelheim is a major, privately-held German pharmaceutical powerhouse with a significant global footprint in human and animal health. Its strategy is built on deep research expertise across multiple therapeutic modalities, including immunology, cardiometabolic diseases, and oncology. The company maintains a robust pipeline and invests heavily in R&D, supported by a stable financial position due to its private ownership structure. Its key challenges include navigating intense therapeutic area competition and the inherent risks of late-stage clinical development.

View full company profile